source
- FDA delays review of Novo's hemophilia A drug denecimig over factory issuesUS regulators have extended the review of Novo's hemophilia A injection, denecimig, because of problems at an unnamed manufacturing facility. The FDA said ongoing remediation activities observed d…
- Genentech pays Alector $100M for preclinical Parkinson’s prospectGenentech is paying Alector $100 million upfront for exclusive rights to a preclinical drug candidate that targets a driver of neurodegeneration in Parkinson’s disease.